Phase 1 Study of Lenvatinib in Combination With Everolimus in Patients With Unresectable Advanced or Metastatic RCC
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 04 Dec 2017
At a glance
- Drugs Lenvatinib (Primary) ; Everolimus
- Indications Renal cell carcinoma
- Focus Adverse reactions
- Sponsors Eisai Co Ltd
- 15 Jan 2016 Status changed from recruiting to active, no longer recruiting, as reported by ClinicalTrials.gov.
- 18 Jun 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.
- 05 Jun 2015 New trial record